Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Income: 2020-2025

Historic Operating Income for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $223.2 million.

  • Apellis Pharmaceuticals' Operating Income rose 572.05% to $223.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.4 million, marking a year-over-year increase of 136.00%. This contributed to the annual value of -$165.0 million for FY2024, which is 68.10% up from last year.
  • Apellis Pharmaceuticals' Operating Income amounted to $223.2 million in Q3 2025, which was up 770.50% from -$33.3 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Operating Income ranged from a high of $223.2 million in Q3 2025 and a low of -$194.3 million during Q2 2021.
  • In the last 3 years, Apellis Pharmaceuticals' Operating Income had a median value of -$62.1 million in 2024 and averaged -$52.3 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Operating Income tumbled by 168.71% in 2021, and later spiked by 572.05% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Operating Income (Quarterly) stood at -$89.4 million in 2021, then tumbled by 83.50% to -$164.1 million in 2022, then surged by 48.48% to -$84.5 million in 2023, then skyrocketed by 69.04% to -$26.2 million in 2024, then surged by 572.05% to $223.2 million in 2025.
  • Its Operating Income was $223.2 million in Q3 2025, compared to -$33.3 million in Q2 2025 and -$83.3 million in Q1 2025.